Therapeutics (NLV-I, exited in sale to Astra Zeneca, 2.5x multiple plus milestones), Relypsa (NLV-I,_ private initially, now public on NASDAQ: RLYP), Convergence/Calchan Pharmaceuticals (NLV-IL, one start up that subsequently split to become 2 separate companies), Durata Therapeutics (NLV-II: IPO - July, 2012, NASDAQ: DRTX), and Ilyp